Archive | November, 2010

PPMI featured in The Lancet Neurology editorial

The Lancet Neurology offers an in-depth analysis of the value of PPMI and makes the case for the potential uses of PD biomarkers. It details the unique study design and standardization incorporated into PPMI and discusses the potential challenges that the PPMI study faces.

Continue reading...

PPMI Clinical Site Recruitment Update

With almost all of the US Clinical Sites activated to recruit for PPMI, 21 subjects are enrolled in the study to date. Sites are getting off to a great start and being creative in their approaches to recruitment for the study.

Continue reading...

Boston Medical Center Connection features PPMI at BMC

The BMCC highlights Boston University and the Boston Medical Center's involvement with PPMI. Dr. Sam Frank, the PI at BU, discusses the focus on and importance of biomarkers in the diagnosis and treatment of PD.

Continue reading...

The Portland Physician Scribe touts PPMI at OHSU

PPMI at OHSU is profiled in The Portland Physician Scribe.

Continue reading...

WQUN radio interview of Dr. Ken Marek on PPMI

Dr. Ken Marek speaks to Quinnipiac University's commercial radio station about the importance of PPMI in the field of PD.

Continue reading...

Study finds that ?-Synuclein is a promising biomarker for PD (Neurology)

A recent paper reports that the levels of ?-synuclein oligomers and the ratio of oligomers to total ?-synuclein in CSF distinguish PD cases from healthy controls and from subjects with other neurodegenerative diseases with high sensitivity and specificity.

Continue reading...

Study Protocol, SOP?s, Data and Specimen Use Guidelines and Publications Policy posted

PPMI was designed with a strong focus on developing standardized protocols for collecting, transferring and storing clinical and imaging data and biological samples. The documents guiding that focus are now available online.

Continue reading...